Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapyYing Gong(Nanfang Hospital), Wilfred T.V. Germeraad(Maastricht University)Journal of Hematology & OncologyMay 1, 202110.1186/s13045-021-01083-5Cited by 364SaveCiteExport RISWatch citationsRelated PapersNKG2A genetic deletion promotes human primary NK cell anti-tumor responses better than an anti-NKG2A monoclonal antibody|Molecular Therapy|2024|28